The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension

Postgraduate Medicine

Volumn 122, Issue 5, 2010, Pages 35-41

  Childress, Ann C ^a   Berry, Sally A ^b  

^a Center for Psychiatry and Behavioral Medicine Inc   (United States)

^b NextWave Pharmaceuticals   (United States)

Author keywords

Attention deficit hyperactivity disorder; Extended release suspension; Methylphenidate; NWP06; Pharmacokinetics

Indexed keywords

METHYLPHENIDATE; NWP 06; UNCLASSIFIED DRUG; CENTRAL STIMULANT AGENT;

ADULT; AGED; AREA UNDER THE CURVE; BLURRED VISION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ECG ABNORMALITY; ELECTROCARDIOGRAPHY; FEMALE; HEART PALPITATION; HEART RATE; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NERVOUSNESS; NORMAL HUMAN; OPEN STUDY; POPULATION RESEARCH; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE; SUSPENSION; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN; VOLUNTEER; ARTICLE; ATTENTION DEFICIT DISORDER; BIOAVAILABILITY; BLOOD; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; HALF LIFE TIME; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; AGED; AREA UNDER CURVE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BIOLOGICAL AVAILABILITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; ELECTROCARDIOGRAPHY; FEMALE; HALF-LIFE; HUMANS; MALE; METHYLPHENIDATE; MIDDLE AGED; VITAL SIGNS;

EID: 78049519413     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.09.2199     Document Type: Review

References (27)

1. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894-921.
2. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics. 2001;108(4):1033-1044.
3. Merikangas KR, He JP, Brody D, Fisher PW, Bourdon K, Koretz DS. Prevalence and treatment of mental disorders among US children in the 2001-2004 NHANES. Pediatrics. 2010;125(1):75-81.
4. Solanto MV, Pope-Boyd SA, Tryon WW, Stepak B. Social functioning in predominantly inattentive and combined subtypes of children with ADHD. J Atten Disord. 2009;13(1):27-35.
5. Loe IM, Feldman HM. Academic and educational outcomes of children with ADHD. J Pediatr Psychol. 2007;32(6):643-654.
6. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry. 1999;56(12):1073-1086.
7. ParentsMedGuide. org. ADHD parent's medication guide. 2007.
8. Information from your family doctor. ADHD in Children. Am Fam Physician. 2009;78(8):1.
9. Cascade E, Kalali AH, Weisler RH. Short-acting versus long-acting medications for the treatment of ADHD. Psychiatry (Edgmont). 2008;5(8):24-27.
10. Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol. 2006;13(1):e50-e62.
11. Meltzer EO, Welch MJ, Ostrom NK. Pill swallowing ability and training in children 6 to 11 years of age. Clin Pediatr (Phila). 2006;45(8):725-733.
12. Findling RL, Wigal SB, Bukstein OG, et al. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials. Clin Ther. 2009;31(8):1844-1855.
13. US Food and Drug Administration. Food and Drug Administration Amendments Act of 2007. 2007:44-45.
14. US Food and Drug Administration. Guidance for Industry: General Considerations for Pediatric Pharmacokinetic Studies for Drugs and Biological Products. 1998.
15. Srinivas NR, Hubbard JW, Quinn D, Midha KK. Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methylphenidate in children with attention deficit hyperactivity disorder. Clin Pharmacol Ther. 1992;52(5):561-568.
16. Aoyama T, Kotaki H, Sasaki T, Sawada Y, Honda Y, Iga T. Nonlinear kinetics of threo-methylphenidate enantiomers in a patient with narcolepsy and in healthy volunteers. Eur J Clin Pharmacol. 1993; 44(1):79-84.
17. Gibaldi M, Perrier D. Pharmacokinetics. Ed 2. New York, NY: Marcel Dekker, Inc; 1982.
18. Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry. 2007;164(7):1035-1043.
19. Adderall XR [package insert]. Wayne, PA: Shire US Inc; 2007.
20. Ritalin LA [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2006.
21. Metadate CD [package insert]. Smyrna, GA: UCB, Inc; 2006.
22. Focalin XR [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2009.
23. Vyvanse [package insert]. Wayne, PA: Shire US Inc; 2010.
24. Daytrana [package insert]. Wayne, PA: Shire US Inc; 2008.
25. Srinivas NR, Hubbard JW, Korchinski ED, Midha KK. Enantioselective pharmacokinetics of dl-threo-methylphenidate in humans. Pharm Res. Jan 1993;10(1):14-21.
26. Wigal SB, Wigal TL. The laboratory school protocol: its origin, use, and new applications. J Atten Disord. 2006;10(1):92-111.
27. Wigal SB, Kollins SH, Childress AC, Squires L. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health. 2009;3(1):17.